News

xience prime xpedition V antiplatelet stents eluting clinical trial study cath

Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate the use...

biotronik orsiro stents drug-eluting cinical trial bioflow

Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to verify the efficacy...

stents drug eluting biosensors tct 2012 transcatheter biomatrix neoflex spectrum

Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.

Patient enrollment has been initiated in a post-market registry for the COMBO Dual Therapy Stent to evaluate its long-term safety and performance in routine clinical practice. The...

Boston Scientific Concludes Evolve II Clinical Trial Enrollment Synergy Stent

In a significant milestone toward obtaining additional key regulatory approvals for the Synergy drug eluting...

Cook Medical is again shipping its Zilver PTX drug-eluting peripheral stent to medical centers in the United States, Japan, Europe and other major markets. The shipments follow a brief period...

Patient enrollment has been initiated in a post-market registry for the Combo Dual Therapy Stent to evaluate its long-term safety and performance in routine clinical practice. The prospective,...

Xience Prime Orsiro Drug Eluting Stent BIO-GLOW II Clinical Study Biotronik Abbo

Primary end-point results from the BIOFLOW-II clinical study demonstrating the non-inferiority of the Biotronik Orsiro Hybrid Drug-Eluting Stent compared to Abbott's Xience Prime. These results...

Final six and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr. Mark Webster at the late-breaking clinical trials session of the EuroPCR...

New long-term data from the DIVERGE study, presented at EuroPCR 2013 by Principal Investigator Dr. Stefan Verheye, Antwerp Cardiovascular Centre, ZNA Middelheim Hospital, Belgium, has shown that...

Xience Xpedition 48 Abbott Vascular CE mark Europe

Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to...

Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral Stent based on its investigation into a small number of complaints that the delivery system of the...

Medtronic Resolute Drug Eluting Stent Dual Antiplatelet Therapy Clinical

Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic Inc. as participants in one of several clinical studies and...

Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) study at Middelheim...

OrbusNeich announced that OrbusNeich Medical GmbH has commenced patent infringement actions in Germany and The Netherlands against Boston Scientific Corp. and its distribution affiliates in those...

Medtronic Resolute Integrity Stent FDA Approval 34, 38 mm

The U.S. Food and Drug Administration (FDA) has approved the 34 and 38 mm lengths of the Medtronic Resolute Integrity drug-eluting stent in diameters of 3, 3.5 and 4 mm with an indication for...

Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES...

Biosensors BioMatrix

The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and cutting balloon catheters....